Oppenheimer & Co. Inc. Purchases 10,000 Shares of MDxHealth SA (NASDAQ:MDXH)

Oppenheimer & Co. Inc. boosted its holdings in MDxHealth SA (NASDAQ:MDXH) by 100.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 20,000 shares of the company’s stock after purchasing an additional 10,000 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in MDxHealth were worth $47,000 at the end of the most recent quarter.

Separately, OneDigital Investment Advisors LLC raised its stake in shares of MDxHealth by 15.3% in the third quarter. OneDigital Investment Advisors LLC now owns 57,726 shares of the company’s stock worth $120,000 after purchasing an additional 7,656 shares during the last quarter.

MDxHealth Price Performance

Shares of NASDAQ:MDXH opened at $1.49 on Monday. The company has a current ratio of 1.54, a quick ratio of 1.45 and a debt-to-equity ratio of 3.14. The stock’s fifty day simple moving average is $1.94 and its two-hundred day simple moving average is $2.13. MDxHealth SA has a 1-year low of $1.49 and a 1-year high of $3.50. The stock has a market cap of $70.46 million, a PE ratio of -0.98 and a beta of 1.37.

MDxHealth (NASDAQ:MDXH) last posted its earnings results on Wednesday, February 26th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.07. MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%. The firm had revenue of $24.74 million for the quarter, compared to analysts’ expectations of $22.67 million. As a group, analysts forecast that MDxHealth SA will post -1.15 EPS for the current fiscal year.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.